Currently Viewing:
American Society of Hematology
Dr Derek Raghavan Explains How Use of Guidelines Can Address Issues of Cost and Variation
May 26, 2018
Dr Derek Raghavan: Evidence-Based Guidelines Will Improve Cancer Outcomes, Reduce Costs
May 09, 2018
Dr Shannon Maude: The Novelty of CAR T Treatments Requires Patient Education
May 01, 2018
Dr Derek Raghavan Provides Best Practices for Implementing Guidelines
April 26, 2018
Dr Thomas LeBlanc on the Importance of Shared Decision Making in Cancer Care
April 18, 2018
Dr Stephen Schuster: Unique CAR T Toxicities Require Provider Education
April 17, 2018
Dr Derek Raghavan Addresses the Concept of "Cookbook Medicine"
April 09, 2018
Dr Nina Shah Outlines New Treatments Being Studied for Multiple Myeloma
April 07, 2018
Dr Thomas LeBlanc: How to Increase Palliative Care Among Patients With Blood Cancer
April 02, 2018
Dr Thomas LeBlanc on Improving End-of-Life Outcomes for Patients With Blood Cancer
March 21, 2018
Dr Thomas LeBlanc: Patients With Blood Cancer and Palliative Care
March 10, 2018
Julie Wolfson: Supporting AYAs Before and After Treatment
January 14, 2018
Dr Julie Wolfson on What Clinicians Need to Understand About Adolescents/Young Adults With ALL
December 30, 2017
Dr Nina Shah on the Impact of New Treatments for Multiple Myeloma
December 29, 2017
Dr Stephen Schuster on Institution Commitments to Deliver CAR T Therapies
December 28, 2017
Dr Shannon Maude Discusses Side Effects of CAR T Therapies
December 25, 2017
Currently Reading
Diagnosing Congenital Neutropenia
December 23, 2017
New Drug Approvals in Leukemia and Lymphoma Presented at ASH 2017
December 18, 2017
Care Utilization Patterns in Sickle Cell Disease: Managing Pain and Care Transitions in AYAs
December 18, 2017

Diagnosing Congenital Neutropenia

Laura Joszt
Physicians caring for patients with severe congenital neutropenia should be ready to detect issues with multiple systems in the body, explained Seth Corey, MD, of the Virginia Commonwealth University and the Massey Cancer Center & Children's Hospital of Richmond, during a session at the 59th American Society of Hematology Annual Meeting and Exposition in Atlanta, Georgia.
Most cases of neutropenia are acquired due to treatment, but there are also congenital neutropenias, which encompass a family of neutropenic disorders.

Physicians caring for patients with severe congenital neutropenia should be ready to detect issues with multiple systems in the body, explained Seth Corey, MD, of the Virginia Commonwealth University and the Massey Cancer Center & Children's Hospital of Richmond, during a session at the 59th American Society of Hematology Annual Meeting and Exposition in Atlanta, Georgia.

He provided the example of how the pancreas is involved in Shwachman–Diamond syndrome, in which the bone marrow malfunctions and some or all types of white blood cells are not created.

“When you have a patient with severe chronic neutropenia, one should look at the eyes, heart, skin, bone, the nervous system…” Corey said.

Individuals with severe congenital neutropenia have a shortage of neutrophils and are prone to recurrent infections. According to Corey, as much as 30% of severe congenital neutropenia is unclassified.

Corey also provided a new workup approach. The current approach begins with a history of onset of neutropenia, documentation, review of past and present infections, family history, and diet. There should also be a physical examination of sites of infection and an exam of skeletal anomalies. A second tier of evaluation includes a bone marrow aspiration and biopsy and blood counts twice a week. Then individuals will typically send off for gene sequencing.

However, Corey introduced a potential third-tier workup. When considering the cost of multiple visits and blood counts, just sending off for gene sequencing may be more cost effective. The third tier is robust next-generation sequencing (NGS) panels to get an idea of the number of different conditions. The cost of NGS panels can be about $2000 at a flat rate, but can be as much as $4000 with a turnover time of 4 to 6 weeks.

“But next generation sequencing is not going to solve everything,” Corey said.

A Canadian study looked at a panel of 72 genes in individuals with known inherited bone marrow failure syndrome, and they were only able to come up with the genetic cause in about 60%. In patients with suspected inherited bone marrow failure syndrome, the success rate was only about 20%, he said.

Corey concluded by summarizing that congenital neutropenias are a “perplexing group of conditions” and that physicians have to go through a thought process to diagnose and treat them.

 
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!